A decision tool for predicting sentinel node accuracy from breast tumor size and grade

Area of Science:

• Oncology
• Surgical Oncology
• Diagnostic Imaging

Background:

• Accurate preoperative prediction of axillary lymph node involvement in breast cancer is essential for effective treatment planning.
• Screen-detected breast cancers often present at earlier stages (T1/T2), necessitating precise staging to guide management.
• Sentinel lymph node biopsy (SLNB) is a standard procedure, but its accuracy depends on factors like tumor characteristics.

Purpose of the Study:

• To develop simple predictive formulas for axillary lymph node involvement in breast cancer.
• To estimate the probability of false-negative results in sentinel node biopsy based on tumor size and grade.
• To provide clinicians with tools for informed decision-making in managing screen-detected breast cancer.

Main Methods:

• Analysis of tumor pathology reports from 4,585 women with T1/T2 breast cancer in New South Wales (1996-1999).
• Linear regression analysis to establish equations predicting nodal positivity based on tumor size and grade.
• Calculation of false-negative SLNB rates using published data and derived formulas.

Main Results:

• Nodal involvement was present in 23.8% of the study cohort.
• A linear relationship was established: node positivity frequency (%) = 1.5 x tumor size (mm) + (2, 6, or 10) for grade I, II, or III tumors, respectively.
• The probability of a false-negative SLNB ranged from 0.8% (5mm, grade I) to 6.0% (50mm, grade III), assuming a 7.5% false-negative rate.

Conclusions:

• Simple, clinically applicable formulas can predict axillary lymph node involvement and SLNB false-negative rates.
• These tools aid surgeons in counseling patients regarding the absolute probability of false-negative SLNB.
• For large T2 tumors, axillary dissection may be preferable to SLNB alone due to under-staging risks and higher positive node probability.